Loading clinical trials...
Loading clinical trials...
A Phase I/II Randomized, Double Blind, Active-controlled, Single Center Clinical Trial for Evaluation of Safety and Efficacy of ATGC-110, An Intramuscularly Administered Clostridium Botulinum Neurotoxin Type A, in Adult Patients With Moderate to Severe Glabellar Frown Lines
Conditions
Interventions
Botulinum toxin type A
Locations
1
South Korea
Nowon Eulji Medical Center
Seoul, South Korea
Start Date
November 1, 2019
Primary Completion Date
April 30, 2020
Completion Date
April 30, 2020
Last Updated
July 9, 2020
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT04249583
Lead Sponsor
ATGC Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions